- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Fistulising Crohn disease
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 923KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 192KB)
Ustekinumab – July 2023
Ustekinumab: Solution concentrate for I.V. infusion 130 mg in 26 mL, Solution for injection 90 mg in 1 mL pre-filled syringe; Stelara®
Last updated
27 October 2023